Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Prognostic role of CD44 expression and neovascularization determined by endoglin (CD105) in glioblastoma patients (CROSBI ID 301459)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Mihić, Josip ; Rotim, Krešimir ; Vučić, Majda ; Hude Dragičević, Ida ; Borić, Marta ; Lugović- Mihić, Liborija Prognostic role of CD44 expression and neovascularization determined by endoglin (CD105) in glioblastoma patients // Acta clinica Croatica, 58 (2019), 3; 455-462. doi: 10.20471/acc.2019.58.03.08

Podaci o odgovornosti

Mihić, Josip ; Rotim, Krešimir ; Vučić, Majda ; Hude Dragičević, Ida ; Borić, Marta ; Lugović- Mihić, Liborija

engleski

Prognostic role of CD44 expression and neovascularization determined by endoglin (CD105) in glioblastoma patients

Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans. Clinically useful molecular markers that help predict response to therapy and prognosis are still rare. The research was conducted in 55 patients with GBM, 26 (47.3%) women and 29 (52.7%) men, mean age 62.58 years. On immunohistochemical analysis, primary antibody to CD44 (dilution 1:50) and primary antibody to endoglin (CD105) (dilution 1:250) were used to evaluate neovascularization. Statistical analysis showed negative correlation between CD44 and survival (p=0.023) (higher expression of CD44 was correlated with shorter survival), but there was no correlation between neovascularization determined by CD105 in GBM and patient survival. Thus, significant individual predictors of longer survival were lower expression of CD44 (p=0.004), higher Karnofsky score (p=0.045), and female gender (p=0.017). The results obtained suggested the possible role of CD44 in the progression and tumor neovascularization of GBM.

glioblastoma ; brain neoplasms ; prognosis ; immunohistochemistry ; CD44 protein ; human ; endoglin

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

58 (3)

2019.

455-462

objavljeno

0353-9466

1333-9451

10.20471/acc.2019.58.03.08

Povezanost rada

Temeljne medicinske znanosti

Poveznice
Indeksiranost